Active ingredientZanamivirCat. No. P-Z005-001CAS 139110-80-8Family · Pharmaceutical analytical standards
Zanamivir
A neuraminidase inhibitor antiviral active against influenza A and B, created in 1989 in Australia by a team led by Peter Colman and Joseph Varghese and approved in 1999 in the United States and Europe; it is taken by inhalation. This family brings together the active ingredient, pharmacopoeial impurities and other impurities.
Did you know?It was designed starting from the X-ray structure of neuraminidase, the enzyme the virus uses to break free from infected cells, and it was the first inhibitor of this class to be developed commercially.
Go to the active ingredient →Active ingredientZanamivirCat. No. P-Z005-001CAS 139110-80-8
Pharmacopoeial impurityZanamivir EP Impurity CCat. No. P-Z005-002CAS 130525-62-1
Pharmacopoeial impurityZanamivir EP Impurity DCat. No. P-Z005-003CAS 179531-53-4
Pharmacopoeial impurityZanamivir EP Impurity ECat. No. P-Z005-004
Pharmacopoeial impurityZanamivir EP Impurity HCat. No. P-Z005-005CAS 179531-57-8
Impurity1H-Pyrazole-1-Carboxamidine HClCat. No. P-Z005-007CAS 4023-02-3
ImpurityZanamivir Azide Methyl EsterCat. No. P-Z005-008CAS 152178-79-5
ImpurityZanamivir Azide Triacetate Methyl EsterCat. No. P-Z005-009CAS 130525-58-5
ImpurityZanamivir DimerCat. No. P-Z005-010No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceZanamivir for assay CRSEDQM code Y0001702Family ZanamivirReference substanceZanamivir hydrate CRSEDQM code Y0001715Family ZanamivirImpurityZanamivir impurity F CRSEDQM code Y0001703Family ZanamivirNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.